Summary of Clinical Use

IMAB362 is being evaluated in Phase 2 clinical trials for advanced gastroesophageal cancer (as monotherapy in NCT01197885) and in combination with the EOX regimen (epirubicin, oxaliplatin and capecitabine) in claudin18.2-positive gastric cancers (NCT01630083).

Mechanism Of Action and Pharmacodynamic Effects

IMAB362 inhibits tumour growth and kills cancer cells by indirect (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity) and direct (antiproliferative and proapoptotic) mechanisms.